Industry Leader articles are written by executives at biopharma companies, consultancies, research firms, and companies that provide services or products to sponsors. The topics are nonpromotional and focused on industrywide business issues.
While the costs and reputational implications associated with pharma data breaches are enough to pay heed to cybersecurity, these compromises can pose a serious threat to patient safety.
Similar to a clinical trial setback, misclassification of independent contractors (ICs) can have a substantial negative impact on a pharma business.
Pharma companies that don’t emphasize risk management and insurance due diligence while adding exposures from new products or services to their policies will see the far-reaching impacts on their budgets.
New research confirms that many of the challenges sponsors face managing clinical trials stem from the disparate nature of processes and systems.
Much has been written about opportunities for improving the drug development process. Although there are many areas ripe for process improvements, let’s focus on the following five.
Many parents can tell a story about the lengths they’ve gone to help their children when no doctor could provide an answer. But there’s one story that stands out to me above the rest because it really drives home the vital need for data sharing, digital collaboration, and the establishment of a connected health ecosystem in the life sciences industry.
Often when we think about inefficiencies in the clinical trial process, we focus on the role of the sponsor or CRO, a particular aspect of the value chain, or new technologies that promote data sharing and faster decision making. While these are critical aspects that drive day-to-day operations, there is another aspect of the value chain that we may be neglecting: the patient side.
With wearables, we now have the means to innovate the “where” and the “how” of patient data capture, creating a 24-hour digital map of physical behaviors.
One of the most vexing and common problems HR professionals face is acquiring and training talent for specific skilled positions, only to see that talent, and the time and money invested in them, walk out the door too soon.
The very nature of many scientific processes creates habitual behaviors. Often these habits are effectively passed from senior lab generations to younger ones. Old habits can be hard to break, especially in a time-pressured lab environment.
The CEO and founder of Seattle Genetics, Clay Siegall, discusses one of the company’s new technologies, sugar-engineered antibodies (SEAs).
The founder and CEO of Seattle Genetics discusses a number of interesting topics, including how he was able to get the founders of Microsoft as early investors in his company.
Clay Siegall, the founder of Seattle Genetics, explains how his company became an unintentional-startup incubator for Alder BioPharmaceuticals.
The Conference Forum’s 2018 R&D Leadership Summit employs the Chatham House Rule, which limits what information can be revealed from the event's proceedings. As one of the only members of the media in the room, Chief Editor Rob Wright shares what he can from this year's event, which had the theme “Growth: Where Will It Come From?”
Here, I aim to offer some additional ideas for how companies can best describe themselves and their products — and how PR agents, journalists, and others might describe them — by achieving the opposite of hype: clarity.